[Hinews] Xafty, a broad-spectrum antiviral candidate from South Korea’s Hyundaibioscience, has secured an official invitation to present its clinical findings and development roadmap at the Rapid Response Partnership Vehicle (RRPV) annual meeting, convened by U.S. health authorities on August 26-27 in Washington, D.C.

This invitation represents more than a standard presentation; it signifies formal endorsement by a recognized U.S. health authority collaborative, garnering global attention. The RRPV program, aimed at addressing public health emergencies like pandemics, supports technology showcases, project alignment, and accelerated evaluations.

The timing is notable. The U.S. Department of Health and Human Services (HHS) recently terminated or downsized 22 mRNA-based next-generation vaccine initiatives, highlighting the constraints of vaccine-focused strategies. This has spurred interest in therapeutic alternatives, with Xafty’s invitation viewed as a key indicator of this shift.

Hyundaibioscience logo (Provided by Hyundaibioscience)
Hyundaibioscience logo (Provided by Hyundaibioscience)


Unlike traditional antivirals targeting specific pathogens, Xafty is designed as a first-of-its-kind universal antiviral, employing a broad inhibitory mechanism to potentially address multiple respiratory viruses. This marks the first instance of a broad-spectrum antiviral being featured on an official U.S. health authority stage.
Byung-joon Bae, president of Hyundaibioscience, underscored the milestone. “Xafty’s recognition as a potential global health security asset carries profound significance,” Bae stated. “We are committed to advancing international health security partnerships and shaping a new framework for pandemic preparedness.”

키워드

#현대바이오사이언스#항바이러스제#제프티
저작권자 © Hinews 무단전재 및 재배포 금지
ad